Clinical Trial Update: Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab for Waldenström macroglobulinemia has completed. The study was conducted by the Eastern Cooperative Oncology Group.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Lymphoma | Phase 2 | Status: COMPLETED